Alain Pralong, co-founder of ENABLE Biotech, a Swiss biotech company focused on cellular therapies, spoke about the company's mission and its efforts to support early-stage startups in the research and development of new medical treatments. The interview took place on September 27 as part of the program Objectif Croissance, hosted by Vincent Touraine. The show, which airs from Monday to Friday on BFM Business, aims to highlight innovative businesses and entrepreneurs working in various sectors of the economy. ENABLE Biotech is known for its work in developing therapies that use cells to treat diseases, an area of medicine that has shown promise in treating conditions such as cancer and autoimmune disorders. During the interview, Pralong emphasized the importance of collaboration between established companies and emerging startups to accelerate the development of life-saving treatments. He also discussed the challenges faced by young biotech firms in securing funding and navigating the complex regulatory landscape. The interview provided insight into how ENABLE Biotech supports startups at different stages of development, from early research to clinical trials. Pralong explained that the company offers both financial backing and technical expertise to help these startups bring their innovations to market more efficiently. He highlighted the importance of fostering a supportive ecosystem for biotech innovation, particularly in Europe. The Objectif Croissance program is part of BFM Business's broader mission to cover economic trends and business innovation. By featuring interviews with entrepreneurs and industry leaders, the show aims to provide viewers and listeners with a deeper understanding of the challenges and opportunities in the business world. The segment with Alain Pralong was one of several focused on the biotechnology sector, which has seen significant growth in recent years.